SYFOVRE (APLS) vs. IZERVAY (Astellas)
Tough month for APLS • 1st: safety issue surfaces for SYFOVRE ⇨ Retinal Vasculitis • Now: IZERVAY approved early ⇨ Good for AMD patients...
${alertText}
Want unlimited access? Try Pro free for 7 days.
SYFOVRE (APLS) vs. IZERVAY (Astellas)
Apellis Pharmaceuticals (APLS)
Biopharma Daily Pulse - 08/24/22
Free Biopharma Daily Pulse - 08/24/22
Big/Suspected Movers FAQ/User Guide
Quarterly Big Mover Biotech Stocks To Watch
Q2 2023 Product Revenue Analyses
BPIQ Q2 2023 Biotech Hedge Fund (13F) Analysis
SYFOVRE (APLS) vs. IZERVAY (Astellas)
BIIB & SAGE: Zuranolone
Apellis Pharmaceuticals (APLS)
Our platform helps you uncover your next biotech investment opportunity